Drug development has focused on reformulating existing drugs and creating alternative methods of drug delivery to improve safety and efficacy. Currently, there are 75 agents in clinical development. Of the 26 agents indicated for neuropathic pain, six specifically target postherpetic neuralgia. Other indications include diabetic peripheral neuropathy, central neuropathic pain due to spinal cord injury or multiple sclerosis and lumbosacral radiculopathy. Nociceptive pain indications include osteoarthritis pain and chronic low back pain.
Sign up for our FREE Pain E-Weekly for more coverage like this sent to your inbox!
Related Articles on Pain Management:
What’s the #1 Quality Pain Management Physicians Look for When Bringing on a New Practice Partner?
Targeted Radiation Alternative Treatment to Surgery for Trigeminal Neuralgia
12 Statistics on Pain Management Case Revenue by Region
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
